Fudan University Shanghai Cancer Center Xuhui Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhu, Yao
NCT06251492: Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Recruiting
2
30
RoW
Stereotactic body radiotherapy, Adebrelimab
Fudan University
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
07/25
12/25
CHAMPION, NCT05717582: Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Not yet recruiting
2
47
RoW
apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection, metastasis-directed therapy with radiation
Fudan University
Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
12/25
12/26
ANGELA, NCT05188911: Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: Trial

Recruiting
N/A
30
RoW
Abiraterone, Prednisone, Androgen deprivation therapy
Fudan University
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Disease
07/22
07/22
Wang, Beihe
FAST Trial, NCT05223582: Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer:

Active, not recruiting
2
34
RoW
Abiraterone acetate, Fluzoparib, Prednisone, Androgen deprivation therapy, Radical Prostatectomy
Fudan University
High-risk Prostate Cancer, Neoadjuvant Therapy
12/23
12/23
CHAMPION, NCT05717582: Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Not yet recruiting
2
47
RoW
apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection, metastasis-directed therapy with radiation
Fudan University
Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
12/25
12/26
ANGELA, NCT05188911: Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: Trial

Recruiting
N/A
30
RoW
Abiraterone, Prednisone, Androgen deprivation therapy
Fudan University
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Disease
07/22
07/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhu, Yao
NCT06251492: Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Recruiting
2
30
RoW
Stereotactic body radiotherapy, Adebrelimab
Fudan University
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
07/25
12/25
CHAMPION, NCT05717582: Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Not yet recruiting
2
47
RoW
apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection, metastasis-directed therapy with radiation
Fudan University
Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
12/25
12/26
ANGELA, NCT05188911: Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: Trial

Recruiting
N/A
30
RoW
Abiraterone, Prednisone, Androgen deprivation therapy
Fudan University
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Disease
07/22
07/22
Wang, Beihe
FAST Trial, NCT05223582: Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer:

Active, not recruiting
2
34
RoW
Abiraterone acetate, Fluzoparib, Prednisone, Androgen deprivation therapy, Radical Prostatectomy
Fudan University
High-risk Prostate Cancer, Neoadjuvant Therapy
12/23
12/23
CHAMPION, NCT05717582: Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Not yet recruiting
2
47
RoW
apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection, metastasis-directed therapy with radiation
Fudan University
Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
12/25
12/26
ANGELA, NCT05188911: Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: Trial

Recruiting
N/A
30
RoW
Abiraterone, Prednisone, Androgen deprivation therapy
Fudan University
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Disease
07/22
07/22

Download Options